A Phase 2, Randomized, Placebo-Controlled Study Evaluating Matrix Metalloproteinase-9 Inhibitor, Andecaliximab, in Patients With Moderately to Severely Active Crohn’s Disease
Journal of Crohn's and Colitis | May 28, 2018 | Volume: No volume available | Issue: No issue available | Pages: No page available
10.1093/ecco-jcc/jjy070
| PMID 29846530